ASGR1 and hepatocellular carcinoma: Chen et al. also reported that dual-targeted CAR-T cells co-expressing glypican-3 (GPC3) and asialoglycoprotein receptor 1 (ASGR1) exerted superior anticancer activity and persistence against single-targeted T cells in two GPC3+ASGR1+ hepatocellular carcinoma (HCC) xenograft models (145).